Literature DB >> 16443789

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes.

Anny H Xiang1, Ruth K Peters, Siri L Kjos, Aura Marroquin, Jose Goico, Cesar Ochoa, Miwa Kawakubo, Thomas A Buchanan.   

Abstract

The Pioglitazone In Prevention Of Diabetes (PIPOD) study was conducted to evaluate beta-cell function, insulin resistance, and the incidence of diabetes during treatment with pioglitazone in Hispanic women with prior gestational diabetes who had completed participation in the Troglitazone In Prevention Of Diabetes (TRIPOD) study. Women who completed the TRIPOD study were offered participation in the PIPOD study for a planned 3 years of drug treatment and 6 months of postdrug washout. Oral glucose tolerance tests were performed annually on pioglitazone and at the end of the postdrug washout. Intravenous glucose tolerance tests (IVGTTs) for assessment of insulin sensitivity and beta-cell function were conducted at baseline, after 1 year on pioglitazone, and at the end of the postdrug washout. Of 95 women who were not diabetic at the end of the TRIPOD study, 89 enrolled in the PIPOD study, 86 completed at least one follow-up visit, and 65 completed all study visits, including the postdrug tests. Comparison of changes in beta-cell compensation for insulin resistance across the TRIPOD and PIPOD studies revealed that pioglitazone stopped the decline in beta-cell function that occurred during placebo treatment in the TRIPOD study and maintained the stability of beta-cell function that had occurred during troglitazone treatment in the TRIPOD study. The risk of diabetes, which occurred at an average rate of 4.6% per year, was lowest in women with the largest reduction in total IVGTT insulin area after 1 year of treatment. The similarity of findings between the PIPOD and TRIPOD studies support a class effect of thiazolidinedione drugs to enhance insulin sensitivity, reduce insulin secretory demands, and preserve pancreatic beta-cell function, all in association with a relatively low rate of type 2 diabetes, in Hispanic women with prior gestational diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16443789      PMCID: PMC1389697          DOI: 10.2337/diabetes.55.02.06.db05-1066

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  16 in total

1.  Diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

2.  TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus.

Authors:  S P Azen; R K Peters; K Berkowitz; S Kjos; A Xiang; T A Buchanan
Journal:  Control Clin Trials       Date:  1998-04

3.  Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function.

Authors:  S E Kahn; R L Prigeon; D K McCulloch; E J Boyko; R N Bergman; M W Schwartz; J L Neifing; W K Ward; J C Beard; J P Palmer
Journal:  Diabetes       Date:  1993-11       Impact factor: 9.461

4.  Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose.

Authors:  R N Bergman; L S Phillips; C Cobelli
Journal:  J Clin Invest       Date:  1981-12       Impact factor: 14.808

5.  Insulin resistance is a poor predictor of type 2 diabetes in individuals with no family history of disease.

Authors:  Allison B Goldfine; Clara Bouche; Robert A Parker; Caroline Kim; Amy Kerivan; J Stuart Soeldner; Blaise C Martin; James H Warram; C Ronald Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-18       Impact factor: 11.205

6.  The defective glucose sensitivity of the B cell in non insulin dependent diabetes. Improvement after twenty hours of normoglycaemia.

Authors:  P Vague; J P Moulin
Journal:  Metabolism       Date:  1982-02       Impact factor: 8.694

7.  Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study.

Authors:  B C Martin; J H Warram; A S Krolewski; R N Bergman; J S Soeldner; C R Kahn
Journal:  Lancet       Date:  1992-10-17       Impact factor: 79.321

8.  Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function.

Authors:  Anny H Xiang; Ruth K Peters; Siri L Kjos; Jose Goico; Cesar Ochoa; Aura Marroquin; Sylvia Tan; Howard N Hodis; Stanley P Azen; Thomas A Buchanan
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

9.  Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans.

Authors:  S M Haffner; H Miettinen; S P Gaskill; M P Stern
Journal:  Diabetes       Date:  1995-12       Impact factor: 9.461

10.  MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test.

Authors:  G Pacini; R N Bergman
Journal:  Comput Methods Programs Biomed       Date:  1986-10       Impact factor: 5.428

View more
  106 in total

1.  The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus.

Authors:  D Gupta; T Kono; C Evans-Molina
Journal:  Diabetes Obes Metab       Date:  2010-12       Impact factor: 6.577

Review 2.  Treatment of prediabetes.

Authors:  Mustafa Kanat; Ralph A DeFronzo; Muhammad A Abdul-Ghani
Journal:  World J Diabetes       Date:  2015-09-25

3.  Chronically increased S6K1 is associated with impaired IRS1 signaling in skeletal muscle of GDM women with impaired glucose tolerance postpartum.

Authors:  Linda A Barbour; Carrie E McCurdy; Teri L Hernandez; Jacob E Friedman
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

Review 4.  The metabolic consequences of sleep deprivation.

Authors:  Kristen L Knutson; Karine Spiegel; Plamen Penev; Eve Van Cauter
Journal:  Sleep Med Rev       Date:  2007-04-17       Impact factor: 11.609

5.  Peroxisome proliferator-activated receptor gamma activation restores islet function in diabetic mice through reduction of endoplasmic reticulum stress and maintenance of euchromatin structure.

Authors:  Carmella Evans-Molina; Reiesha D Robbins; Tatsuyoshi Kono; Sarah A Tersey; George L Vestermark; Craig S Nunemaker; James C Garmey; Tye G Deering; Susanna R Keller; Bernhard Maier; Raghavendra G Mirmira
Journal:  Mol Cell Biol       Date:  2009-02-23       Impact factor: 4.272

Review 6.  Is the metabolic syndrome a real clinical entity and should it receive drug treatment?

Authors:  Tamara Darsow; David Kendall; David Maggs
Journal:  Curr Diab Rep       Date:  2006-11       Impact factor: 4.810

Review 7.  Are thiazolidinediones good or bad for the heart?

Authors:  Angela M Taylor; Coleen A McNamara
Journal:  Curr Diab Rep       Date:  2006-11       Impact factor: 4.810

8.  Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study.

Authors:  R A DeFronzo; M A Banerji; G A Bray; T A Buchanan; S Clement; R R Henry; A E Kitabchi; S Mudaliar; N Musi; R Ratner; P Reaven; D C Schwenke; F D Stentz; D Tripathy
Journal:  Diabetologia       Date:  2009-12-10       Impact factor: 10.122

9.  Risk of development of diabetes mellitus after diagnosis of gestational diabetes.

Authors:  Denice S Feig; Bernard Zinman; Xuesong Wang; Janet E Hux
Journal:  CMAJ       Date:  2008-07-29       Impact factor: 8.262

10.  Variation in IGF2BP2 interacts with adiposity to alter insulin sensitivity in Mexican Americans.

Authors:  Xia Li; Hooman Allayee; Anny H Xiang; Enrique Trigo; Jaana Hartiala; Jean M Lawrence; Thomas A Buchanan; Richard M Watanabe
Journal:  Obesity (Silver Spring)       Date:  2009-01-15       Impact factor: 5.002

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.